Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Harmony Biosciences Holdings Inc (NASDAQ: HRMY) closed at $32.29 down -1.28% from its previous closing price of $32.71. In other words, the price has decreased by -$1.28 from its previous closing price. On the day, 0.59 million shares were traded. HRMY stock price reached its highest trading level at $33.06 during the session, while it also had its lowest trading level at $31.97.
Ratios:
For a deeper understanding of Harmony Biosciences Holdings Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.49 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.36. For the most recent quarter (mrq), Quick Ratio is recorded 3.20 and its Current Ratio is at 3.24. In the meantime, Its Debt-to-Equity ratio is 0.38 whereas as Long-Term Debt/Eq ratio is at 0.28.
On September 10, 2024, UBS started tracking the stock assigning a Buy rating and target price of $56.
On June 21, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $48.Citigroup initiated its Buy rating on June 21, 2024, with a $48 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 01 ’24 when Valor IV Pharma Holdings, LLC sold 4,000,000 shares for $30.30 per share. The transaction valued at 121,210,000 led to the insider holds 7,218,033 shares of the business.
Valor IV Pharma Holdings, LLC sold 600,000 shares of HRMY for $18,181,500 on Nov 05 ’24. The 10% Owner now owns 6,618,033 shares after completing the transaction at $30.30 per share. On Nov 01 ’24, another insider, Marshman Fund Trust II, who serves as the 10% Owner of the company, sold 4,000,000 shares for $30.30 each. As a result, the insider received 121,210,000 and left with 6,651,120 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HRMY now has a Market Capitalization of 1841540736 and an Enterprise Value of 1616306560. As of this moment, Harmony’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.29, and their Forward P/E ratio for the next fiscal year is 10.15. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.60. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.70 while its Price-to-Book (P/B) ratio in mrq is 3.09. Its current Enterprise Value per Revenue stands at 2.37 whereas that against EBITDA is 8.099.
Stock Price History:
Over the past 52 weeks, HRMY has reached a high of $41.61, while it has fallen to a 52-week low of $28.14. The 50-Day Moving Average of the stock is -6.18%, while the 200-Day Moving Average is calculated to be -2.22%.
Shares Statistics:
For the past three months, HRMY has traded an average of 754.83K shares per day and 447860 over the past ten days. A total of 57.03M shares are outstanding, with a floating share count of 40.49M. Insiders hold about 29.00% of the company’s shares, while institutions hold 66.01% stake in the company. Shares short for HRMY as of 1732838400 were 5445550 with a Short Ratio of 7.21, compared to 1730332800 on 6056425. Therefore, it implies a Short% of Shares Outstanding of 5445550 and a Short% of Float of 42.119997999999995.
Earnings Estimates
The current assessment of Harmony Biosciences Holdings Inc (HRMY) involves the perspectives of 5.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.89, with high estimates of $1.17 and low estimates of $0.63.
Analysts are recommending an EPS of between $4.04 and $2.43 for the fiscal current year, implying an average EPS of $3.42. EPS for the following year is $4.43, with 5.0 analysts recommending between $5.09 and $3.32.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $198.84M this quarter.It ranges from a high estimate of $203.8M to a low estimate of $192.53M. As of the current estimate, Harmony Biosciences Holdings Inc’s year-ago sales were $168.41MFor the next quarter, 8 analysts are estimating revenue of $182.29M. There is a high estimate of $188.08M for the next quarter, whereas the lowest estimate is $176.8M.
A total of 8 analysts have provided revenue estimates for HRMY’s current fiscal year. The highest revenue estimate was $717.2M, while the lowest revenue estimate was $706M, resulting in an average revenue estimate of $712.29M. In the same quarter a year ago, actual revenue was $582.02MBased on 8 analysts’ estimates, the company’s revenue will be $845.23M in the next fiscal year. The high estimate is $889.8M and the low estimate is $790.71M.
